Pfizer announced that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab) as an option for preventing bleeding episodes in people with severe haemophilia B.
Moleculin Biotech, a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application.
Isarna Therapeutics presented final positive results from its Phase II BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on 6th May.
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints.
Orchestra BioMed Holdings has announced that FDA has approved its Investigational Device Exemption amendment to initiate an updated design of the Company’s planned Virtue SAB in the Treatment of Coronary ISR Trial.
Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months.
Ramesh Jagadeesan, vice president, head of analytical services at Recipharm shares his insights on the role of analytical services in drug development.
Ferrer, a pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement.
